PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26518722-3	2015	In the context of antibody-mediated targeted cancer therapy, we evaluated the anti-tumor activity and therapeutic efficacy of Doxil, and that of Doxil modified with a monoclonal antibody (mAb) against CD44, which is one of the most well-known surface markers associated with Cancer Stem Cells (CSCs).	liposomal doxorubicin	145-150	CD44 antigen	Mus musculus	201-205	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	132-137	CD44 antigen	Mus musculus	118-122	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	132-137	CD44 antigen	Mus musculus	139-143	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	132-137	CD44 antigen	Mus musculus	139-143	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	144-149	CD44 antigen	Mus musculus	118-122	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	144-149	CD44 antigen	Mus musculus	139-143	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	144-149	CD44 antigen	Mus musculus	139-143	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	144-149	CD44 antigen	Mus musculus	118-122	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	144-149	CD44 antigen	Mus musculus	139-143	
26518722-4	2015	Flow cytometry analyses and confocal laser scanning microscopy results showed significant enhanced cellular uptake of CD44-targeted Doxil (CD44-Doxil) in CD44-positive C-26 cells compared to Doxil.	liposomal doxorubicin	144-149	CD44 antigen	Mus musculus	139-143	
26518722-5	2015	However, CD44-negative NIH-3T3 cells showed a similar uptake and in vitro cytotoxicity with both CD44-Doxil and non-targeted Doxil.	liposomal doxorubicin	101-107	CD44 antigen	Mus musculus	9-13	
26518722-5	2015	However, CD44-negative NIH-3T3 cells showed a similar uptake and in vitro cytotoxicity with both CD44-Doxil and non-targeted Doxil.	liposomal doxorubicin	102-107	CD44 antigen	Mus musculus	9-13	
26518722-5	2015	However, CD44-negative NIH-3T3 cells showed a similar uptake and in vitro cytotoxicity with both CD44-Doxil and non-targeted Doxil.	liposomal doxorubicin	102-107	CD44 antigen	Mus musculus	97-101	
26518722-6	2015	In BALB/c mice bearing C-26 murine carcinoma, CD44-Doxil groups exhibited significantly higher doxorubicin concentration (than Doxil) inside the tumor cells, while their circulation time and distribution profile remained comparable.	liposomal doxorubicin	51-56	CD44 antigen	Mus musculus	46-50	
26518722-6	2015	In BALB/c mice bearing C-26 murine carcinoma, CD44-Doxil groups exhibited significantly higher doxorubicin concentration (than Doxil) inside the tumor cells, while their circulation time and distribution profile remained comparable.	liposomal doxorubicin	127-132	CD44 antigen	Mus musculus	46-50	
26518722-7	2015	CD44-Doxil at doses of either 10 or 15 mg/kg resulted in superior tumor growth inhibition and higher inclination to tumor, indicating the potential of anti-CD44 mAb targeting in therapeutic efficacy improvement.	liposomal doxorubicin	5-10	CD44 antigen	Mus musculus	0-4	
26518722-7	2015	CD44-Doxil at doses of either 10 or 15 mg/kg resulted in superior tumor growth inhibition and higher inclination to tumor, indicating the potential of anti-CD44 mAb targeting in therapeutic efficacy improvement.	liposomal doxorubicin	5-10	CD44 antigen	Mus musculus	156-160